Once released, VEGF induces severalresponses, including cell survival, migration, and further differentiation.Therefore, the use of VEGF as a target in cancer treatment was explored and in 2004,the first anti-VEGF drug, bevacizumab, was approved. The gene discussed is VEGFA; the disease is cancer.